spacer
home > pmps > spring 2007 > unmasking the blind of over-encapsulation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Unmasking the Blind of Over-Encapsulation

Richard Shannon at Almac Clinical Services, assesses the impact of over-encapsulation in the clinical supplies industry

A study conducted by the Tufts Center for the Study of Drug Development estimated that the cost of bringing a novel compound to market is in excess of $800 million, so the need to prove superior efficacy and safety when compared to an already marketed product is of critical importance. When developing protocol designs, blinding or masking of clinical supplies is an integral part of many studies. This can help remove both investigator and patient bias due to the visibility of the marketed product, and can limit any potential placebo effect. One of the extensively used mechanisms available to sponsor companies to promote blinding is the over-encapsulation of tablets or capsules.

Over-encapsulation is now a widely accepted mechanism used throughout the clinical supplies industry, and while the process itself may appear relatively straightforward, packaging for clinical supplies is a complex process that is strictly controlled by good manufacturing practice (GMP). The principle of overencapsulation is simply the addition of a product or products to a hard gelatin capsule, which may or may not be backfilled with an inactive bulk agent or excipient. This process can be used for comparator products, investigational medicinal products (IMP) and/or placebos, providing an output of visually identical capsules for each product or strength, thus maintaining the blind and removing any potential bias.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Richard Shannon joined Almac Clinical Services (formerly Clinical Trial Services) in 1999 and has served in various business development functions during this time. He began his Almac career in Europe, before relocating to Almac, US, in 2001, where he gained valuable insight into the US clinical trial supply market and was integral in establishing a new business development team. Richard returned to Almac Europe in October 2005, and was appointed Head of Business Development (Europe). Prior to joining Almac, Richard was employed by MDS Harris (now MDS Pharmaservices) where he performed various clinical trial conduct roles. Richard holds a BSc (Hons) from Queen’s University, Belfast.
spacer
Richard Shannon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

Trial Timelines

Thomson Reuters

Save resources with accurate trial length projections. How analytics based on curated content can deliver insight for clinical strategies.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement